JP6893218B2 - ＲＯＲγｔのモジュレータとしての６−アミノピリジン−３−イルチアゾール - Google Patents
ＲＯＲγｔのモジュレータとしての６−アミノピリジン−３−イルチアゾール Download PDFInfo
- Publication number
- JP6893218B2 JP6893218B2 JP2018556297A JP2018556297A JP6893218B2 JP 6893218 B2 JP6893218 B2 JP 6893218B2 JP 2018556297 A JP2018556297 A JP 2018556297A JP 2018556297 A JP2018556297 A JP 2018556297A JP 6893218 B2 JP6893218 B2 JP 6893218B2
- Authority
- JP
- Japan
- Prior art keywords
- thiazole
- bromo
- carbonyl
- pyridine
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *N(CC1)CC1O Chemical compound *N(CC1)CC1O 0.000 description 52
- BKUQVCVAPOWJLW-UHFFFAOYSA-N CCC1(CC1)C(F)(F)F Chemical compound CCC1(CC1)C(F)(F)F BKUQVCVAPOWJLW-UHFFFAOYSA-N 0.000 description 4
- WQNDAVGXCMQSSH-UHFFFAOYSA-N CC(CC1)CCC1(F)F Chemical compound CC(CC1)CCC1(F)F WQNDAVGXCMQSSH-UHFFFAOYSA-N 0.000 description 3
- OYCKYHILVXROPX-UHFFFAOYSA-N CC1(CCC1)C(F)(F)F Chemical compound CC1(CCC1)C(F)(F)F OYCKYHILVXROPX-UHFFFAOYSA-N 0.000 description 3
- ULZCOWMSBOJCLT-UHFFFAOYSA-N CN(CC1)CCS1(=O)=O Chemical compound CN(CC1)CCS1(=O)=O ULZCOWMSBOJCLT-UHFFFAOYSA-N 0.000 description 3
- HUKCWCNQJHRMBR-UHFFFAOYSA-N CC1(CC1)C(F)(F)F Chemical compound CC1(CC1)C(F)(F)F HUKCWCNQJHRMBR-UHFFFAOYSA-N 0.000 description 2
- FFZKNVBZDGWYEY-UHFFFAOYSA-N CCC1(CCC1)C(F)(F)F Chemical compound CCC1(CCC1)C(F)(F)F FFZKNVBZDGWYEY-UHFFFAOYSA-N 0.000 description 2
- FXCBWVLBHWCKQU-UHFFFAOYSA-N CC(C)(C)C(CC1)CCS1(=O)=O Chemical compound CC(C)(C)C(CC1)CCS1(=O)=O FXCBWVLBHWCKQU-UHFFFAOYSA-N 0.000 description 1
- XKWRUTXTAAPAPO-UHFFFAOYSA-N CC(C)(CNC(c1nc(C(N(CC2)CCC2F)=O)c(-c2c(C(F)(F)F)cc(NC(C3)CC3(F)F)nc2)[s]1)=O)O Chemical compound CC(C)(CNC(c1nc(C(N(CC2)CCC2F)=O)c(-c2c(C(F)(F)F)cc(NC(C3)CC3(F)F)nc2)[s]1)=O)O XKWRUTXTAAPAPO-UHFFFAOYSA-N 0.000 description 1
- XIVVZVXBQPRACC-UHFFFAOYSA-N CC(C)(CNC(c1nc(C(N(CC2)CCC2F)=O)c(-c2cc(C(F)(F)F)c(NC(C3)CC3(F)F)nc2)[s]1)=O)O Chemical compound CC(C)(CNC(c1nc(C(N(CC2)CCC2F)=O)c(-c2cc(C(F)(F)F)c(NC(C3)CC3(F)F)nc2)[s]1)=O)O XIVVZVXBQPRACC-UHFFFAOYSA-N 0.000 description 1
- CGYZYBZBFNQVPH-UHFFFAOYSA-N CC(C)(CNC(c1nc(C(N(CC2)CCC2F)=O)c(-c2cc(C(F)(F)F)c(NC3CCCCC3)nc2)[s]1)=O)O Chemical compound CC(C)(CNC(c1nc(C(N(CC2)CCC2F)=O)c(-c2cc(C(F)(F)F)c(NC3CCCCC3)nc2)[s]1)=O)O CGYZYBZBFNQVPH-UHFFFAOYSA-N 0.000 description 1
- OZHCQESMORFVTF-UHFFFAOYSA-N CC(C)(CNC(c1nc(CN(CCCC2)CC2(F)F)c(-c2c(C(F)(F)F)cc(NCC3(CC3)C(F)(F)F)nc2)[s]1)=O)O Chemical compound CC(C)(CNC(c1nc(CN(CCCC2)CC2(F)F)c(-c2c(C(F)(F)F)cc(NCC3(CC3)C(F)(F)F)nc2)[s]1)=O)O OZHCQESMORFVTF-UHFFFAOYSA-N 0.000 description 1
- NTFYRCGZVNLHBM-UHFFFAOYSA-N CC(C)S(Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(CC2)CCC2F)=O)nc(C(NCC(C)(C)O)=O)[s]1)(=O)=O Chemical compound CC(C)S(Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(CC2)CCC2F)=O)nc(C(NCC(C)(C)O)=O)[s]1)(=O)=O NTFYRCGZVNLHBM-UHFFFAOYSA-N 0.000 description 1
- SSQQKIROPQRDMR-LSLKUGRBSA-N CC(C1CCC1)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(C2)[C@@H](C)CC2(F)F)=O)nc(C(NCC(C)(C)O)=O)[s]1 Chemical compound CC(C1CCC1)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(C2)[C@@H](C)CC2(F)F)=O)nc(C(NCC(C)(C)O)=O)[s]1 SSQQKIROPQRDMR-LSLKUGRBSA-N 0.000 description 1
- ZXJOUDPJLBPZPV-UHFFFAOYSA-N CC1(CN(C)C1)O Chemical compound CC1(CN(C)C1)O ZXJOUDPJLBPZPV-UHFFFAOYSA-N 0.000 description 1
- LZCLRPYCYCEKBS-UHFFFAOYSA-N CC1(CN(C)CC1)O Chemical compound CC1(CN(C)CC1)O LZCLRPYCYCEKBS-UHFFFAOYSA-N 0.000 description 1
- LDLAEUFQUOXALI-UHFFFAOYSA-N CC1(CNC1)O Chemical compound CC1(CNC1)O LDLAEUFQUOXALI-UHFFFAOYSA-N 0.000 description 1
- SJUSLESYVZFLTK-ZDUSSCGKSA-N CCC(C)(C)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(C2)[C@@H](C)CC2(F)F)=O)nc(C(NCC(C)(C)O)=O)[s]1 Chemical compound CCC(C)(C)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(C2)[C@@H](C)CC2(F)F)=O)nc(C(NCC(C)(C)O)=O)[s]1 SJUSLESYVZFLTK-ZDUSSCGKSA-N 0.000 description 1
- LCWHHPSANJWPQM-BBRMVZONSA-N CC[C@@H](C(F)(F)F)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N2[C@@H](C)CCCC2)=O)nc(C(NCC(C)(C)O)=O)[s]1 Chemical compound CC[C@@H](C(F)(F)F)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N2[C@@H](C)CCCC2)=O)nc(C(NCC(C)(C)O)=O)[s]1 LCWHHPSANJWPQM-BBRMVZONSA-N 0.000 description 1
- NJVOYZIVBVDIMN-SSDOTTSWSA-N CC[C@H](C(F)(F)F)Nc(nc1)cc(C(F)(F)F)c1Br Chemical compound CC[C@H](C(F)(F)F)Nc(nc1)cc(C(F)(F)F)c1Br NJVOYZIVBVDIMN-SSDOTTSWSA-N 0.000 description 1
- VEBAEMDIPHZTFK-UHFFFAOYSA-N CN(C1)CC1(C1)CS1(=O)=O Chemical compound CN(C1)CC1(C1)CS1(=O)=O VEBAEMDIPHZTFK-UHFFFAOYSA-N 0.000 description 1
- IJVQAJHYYRVZNE-UHFFFAOYSA-N CN(C1)CC1O Chemical compound CN(C1)CC1O IJVQAJHYYRVZNE-UHFFFAOYSA-N 0.000 description 1
- ASGHRQMQKYGSJP-UHFFFAOYSA-N CN(C1)CC1S(C)(=O)=O Chemical compound CN(C1)CC1S(C)(=O)=O ASGHRQMQKYGSJP-UHFFFAOYSA-N 0.000 description 1
- LFHMKODCPPOLIB-UHFFFAOYSA-N CN(CC1)CCC1(F)F Chemical compound CN(CC1)CCC1(F)F LFHMKODCPPOLIB-UHFFFAOYSA-N 0.000 description 1
- VDOLWAQYIDIFME-UHFFFAOYSA-N CN(CC1O)CC1F Chemical compound CN(CC1O)CC1F VDOLWAQYIDIFME-UHFFFAOYSA-N 0.000 description 1
- MFYXNTFIFHINFW-UHFFFAOYSA-N CN1CC(CO)C1 Chemical compound CN1CC(CO)C1 MFYXNTFIFHINFW-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- IJJGOAIJDMYZJR-UHFFFAOYSA-N CN1COCCC1 Chemical compound CN1COCCC1 IJJGOAIJDMYZJR-UHFFFAOYSA-N 0.000 description 1
- FLMRQKUFUGFDIP-KBPBESRZSA-N C[C@@H](C(C)(C)O)NC(c1nc(C(N2[C@@H](C)CCC2)=O)c(-c2c(C(F)(F)F)cc(NC(C)(C)C)nc2)[s]1)=O Chemical compound C[C@@H](C(C)(C)O)NC(c1nc(C(N2[C@@H](C)CCC2)=O)c(-c2c(C(F)(F)F)cc(NC(C)(C)C)nc2)[s]1)=O FLMRQKUFUGFDIP-KBPBESRZSA-N 0.000 description 1
- UZWQMHPVOYAYCC-YFKPBYRVSA-N C[C@@H](C1)N(C)CC1(F)F Chemical compound C[C@@H](C1)N(C)CC1(F)F UZWQMHPVOYAYCC-YFKPBYRVSA-N 0.000 description 1
- AXHYOPXMTAJNTN-GJZGRUSLSA-N C[C@@H](C1CC1)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N2[C@@H](C)CCCC2)=O)nc(C(NCC(C)(C)O)=O)[s]1 Chemical compound C[C@@H](C1CC1)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N2[C@@H](C)CCCC2)=O)nc(C(NCC(C)(C)O)=O)[s]1 AXHYOPXMTAJNTN-GJZGRUSLSA-N 0.000 description 1
- OQMNYHOSLVWKOM-JQRITLKVSA-N C[C@@H](CC(C1)(F)F)N1C(c1c(-c2c(C(F)(F)F)cc(NC3(C)CCC3)nc2)[s]c(C(NC(COC2)C2O)=O)n1)=O Chemical compound C[C@@H](CC(C1)(F)F)N1C(c1c(-c2c(C(F)(F)F)cc(NC3(C)CCC3)nc2)[s]c(C(NC(COC2)C2O)=O)n1)=O OQMNYHOSLVWKOM-JQRITLKVSA-N 0.000 description 1
- OQMNYHOSLVWKOM-VBNZEHGJSA-N C[C@@H](CC(C1)(F)F)N1C(c1c(-c2c(C(F)(F)F)cc(NC3(C)CCC3)nc2)[s]c(C(N[C@@H](COC2)[C@@H]2O)=O)n1)=O Chemical compound C[C@@H](CC(C1)(F)F)N1C(c1c(-c2c(C(F)(F)F)cc(NC3(C)CCC3)nc2)[s]c(C(N[C@@H](COC2)[C@@H]2O)=O)n1)=O OQMNYHOSLVWKOM-VBNZEHGJSA-N 0.000 description 1
- BYUCTWJPDDDFAY-LBPRGKRZSA-N C[C@@H](CC(C1)(F)F)N1C(c1c(-c2c(C(F)(F)F)cc(NCC(C)(C)C)nc2)[s]c(C(NC(C2)CS2(=O)=O)=O)n1)=O Chemical compound C[C@@H](CC(C1)(F)F)N1C(c1c(-c2c(C(F)(F)F)cc(NCC(C)(C)C)nc2)[s]c(C(NC(C2)CS2(=O)=O)=O)n1)=O BYUCTWJPDDDFAY-LBPRGKRZSA-N 0.000 description 1
- ZUQLNYVEGLPBSE-AWEZNQCLSA-N C[C@@H](CC1)N1C(c1c(-c2c(C(F)(F)F)cc(NC3CCCCC3)nc2)[s]c(C(NCC(C)(C)O)=O)n1)=O Chemical compound C[C@@H](CC1)N1C(c1c(-c2c(C(F)(F)F)cc(NC3CCCCC3)nc2)[s]c(C(NCC(C)(C)O)=O)n1)=O ZUQLNYVEGLPBSE-AWEZNQCLSA-N 0.000 description 1
- DWDPVAYOSPIDPN-FZMZJTMJSA-N C[C@@H](CCC1)N1C(c1c(-c(c(C(F)(F)F)c2)cnc2NC(C)(C)C)[s]c(C(NC[C@@H](C(F)(F)F)O)=O)n1)=O Chemical compound C[C@@H](CCC1)N1C(c1c(-c(c(C(F)(F)F)c2)cnc2NC(C)(C)C)[s]c(C(NC[C@@H](C(F)(F)F)O)=O)n1)=O DWDPVAYOSPIDPN-FZMZJTMJSA-N 0.000 description 1
- FGBKWLBVRXIVFL-AWEZNQCLSA-N C[C@@H](CCC1)N1C(c1c(-c2c(C(F)(F)F)cc(NC3(C)CCC3)nc2)[s]c(C(NCC(C)(C)O)=O)n1)=O Chemical compound C[C@@H](CCC1)N1C(c1c(-c2c(C(F)(F)F)cc(NC3(C)CCC3)nc2)[s]c(C(NCC(C)(C)O)=O)n1)=O FGBKWLBVRXIVFL-AWEZNQCLSA-N 0.000 description 1
- WWYFGGBPHAGVED-KPPDAEKUSA-N C[C@H](C(C)(C)O)NC(c1nc(C(N2C3CCC2CC3)=O)c[s]1)=O Chemical compound C[C@H](C(C)(C)O)NC(c1nc(C(N2C3CCC2CC3)=O)c[s]1)=O WWYFGGBPHAGVED-KPPDAEKUSA-N 0.000 description 1
- HCCKCORYOFXGBP-CYBMUJFWSA-N C[C@H](C1CC1)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(CC2)CCC2F)=O)nc(C(NCC(C)(C)O)=O)[s]1 Chemical compound C[C@H](C1CC1)Nc(nc1)cc(C(F)(F)F)c1-c1c(C(N(CC2)CCC2F)=O)nc(C(NCC(C)(C)O)=O)[s]1 HCCKCORYOFXGBP-CYBMUJFWSA-N 0.000 description 1
- OATMVWFADSXPDV-OLZOCXBDSA-N C[C@H](CO)NC(c1nc(C(N2[C@@H](C)CCC2)=O)c(-c2c(C(F)(F)F)cc(NC(C)(C)C)nc2)[s]1)=O Chemical compound C[C@H](CO)NC(c1nc(C(N2[C@@H](C)CCC2)=O)c(-c2c(C(F)(F)F)cc(NC(C)(C)C)nc2)[s]1)=O OATMVWFADSXPDV-OLZOCXBDSA-N 0.000 description 1
- UMSFDYZKIMGBHB-UHFFFAOYSA-N C[Ne]1(C)CC(CC2)OC2C1 Chemical compound C[Ne]1(C)CC(CC2)OC2C1 UMSFDYZKIMGBHB-UHFFFAOYSA-N 0.000 description 1
- OQJXQBMTHAUQEP-UHFFFAOYSA-N FC(c(cc(NC(CC1)CCC1(F)F)nc1)c1Br)(F)F Chemical compound FC(c(cc(NC(CC1)CCC1(F)F)nc1)c1Br)(F)F OQJXQBMTHAUQEP-UHFFFAOYSA-N 0.000 description 1
- SODQYQMDFQTDSH-UHFFFAOYSA-N N#Cc1c(C(F)(F)F)ccnc1NC1CCCCC1 Chemical compound N#Cc1c(C(F)(F)F)ccnc1NC1CCCCC1 SODQYQMDFQTDSH-UHFFFAOYSA-N 0.000 description 1
- BMRJPWHUHXMZJY-UHFFFAOYSA-N O=C(c1c2cccc1)N(C1CC1)C2=O Chemical compound O=C(c1c2cccc1)N(C1CC1)C2=O BMRJPWHUHXMZJY-UHFFFAOYSA-N 0.000 description 1
- AJNSMCQJMBEBMD-UHFFFAOYSA-N OC(c1c[s]c(C(NC(CC2)CCS2(=O)=O)=O)n1)=O Chemical compound OC(c1c[s]c(C(NC(CC2)CCS2(=O)=O)=O)n1)=O AJNSMCQJMBEBMD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Image Processing (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328074P | 2016-04-27 | 2016-04-27 | |
| US62/328,074 | 2016-04-27 | ||
| PCT/US2017/029531 WO2017189661A1 (en) | 2016-04-27 | 2017-04-26 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγT |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515924A JP2019515924A (ja) | 2019-06-13 |
| JP2019515924A5 JP2019515924A5 (https=) | 2019-07-18 |
| JP6893218B2 true JP6893218B2 (ja) | 2021-06-23 |
Family
ID=59215941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556297A Expired - Fee Related JP6893218B2 (ja) | 2016-04-27 | 2017-04-26 | ＲＯＲγｔのモジュレータとしての６−アミノピリジン−３−イルチアゾール |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US10975068B2 (https=) |
| EP (1) | EP3448856B1 (https=) |
| JP (1) | JP6893218B2 (https=) |
| KR (1) | KR20180135962A (https=) |
| CN (1) | CN109415358B (https=) |
| AR (1) | AR108344A1 (https=) |
| AU (1) | AU2017255525A1 (https=) |
| BR (1) | BR112018071942A2 (https=) |
| CA (1) | CA3022318A1 (https=) |
| CL (1) | CL2018003044A1 (https=) |
| CO (1) | CO2018011633A2 (https=) |
| CR (1) | CR20180505A (https=) |
| EA (1) | EA036318B1 (https=) |
| EC (1) | ECSP18088146A (https=) |
| ES (1) | ES2906258T3 (https=) |
| IL (1) | IL262381A (https=) |
| MA (1) | MA44772A (https=) |
| MX (1) | MX2018013143A (https=) |
| NI (1) | NI201800109A (https=) |
| PE (1) | PE20190150A1 (https=) |
| PH (1) | PH12018502209A1 (https=) |
| SG (1) | SG11201809162XA (https=) |
| SV (1) | SV2018005772A (https=) |
| TW (1) | TW201803869A (https=) |
| UY (1) | UY37213A (https=) |
| WO (1) | WO2017189661A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201803869A (zh) * | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| JP2021517563A (ja) * | 2018-03-12 | 2021-07-26 | エスカリア バイオサイエンシーズ，ビーブイ | 二環式ＲＯＲγモジュレーター |
| KR20210060367A (ko) | 2018-03-12 | 2021-05-26 | 에스칼리에 바이오사이언시스, 비브이 | 스피로사이클릭 ror-감마 조절제 |
| ES2925473T3 (es) * | 2018-06-18 | 2022-10-18 | Janssen Pharmaceutica Nv | Pirazoles de piridinilo como moduladores de RORyt |
| CA3103770A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of roryt |
| EP3806958B1 (en) | 2018-06-18 | 2022-09-07 | Janssen Pharmaceutica NV | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
| JP2021528405A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
| EP0772606A1 (en) | 1994-07-27 | 1997-05-14 | G.D. SEARLE & CO. | Substituted thiazoles for the treatment of inflammation |
| WO2002083111A2 (en) | 2001-04-16 | 2002-10-24 | Tanabe Seiyaku Co., Ltd. | Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
| IL160327A0 (en) | 2001-08-13 | 2004-07-25 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| CA2463441A1 (en) | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| EP1874734A1 (en) | 2005-02-16 | 2008-01-09 | Solvay Pharmaceuticals B.V. | 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators |
| WO2006124687A1 (en) | 2005-05-12 | 2006-11-23 | University Of Medicine And Dentistry Of New Jersey | Opioid receptor subtype-selective agents |
| CA2639910A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
| WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| EP2586311B1 (de) | 2008-07-17 | 2016-12-14 | Bayer CropScience AG | Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel |
| TWI548411B (zh) | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| UA110097C2 (uk) | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| CA2771710A1 (en) | 2009-09-18 | 2011-03-24 | Zalicus Pharmaceuticals Ltd. | Aryl sulphone derivatives as calcium channel blockers |
| AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| US9101600B2 (en) | 2010-03-11 | 2015-08-11 | New York University | Compounds as RORγt modulators and uses thereof |
| ES2703176T3 (es) | 2010-03-11 | 2019-03-07 | Univ New York | Compuestos amido como moduladores de RORgammat y usos de los mismos |
| WO2011115892A1 (en) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| US9505798B2 (en) | 2010-11-29 | 2016-11-29 | New York University | Steroid compounds as RORyt modulators and uses thereof |
| JP5981350B2 (ja) | 2010-12-28 | 2016-08-31 | ライオン株式会社 | 口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム |
| US9012651B2 (en) | 2011-03-24 | 2015-04-21 | Abbvie Inc. | TRPV3 modulators |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| US9133128B2 (en) | 2011-06-17 | 2015-09-15 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
| EP2738170B1 (en) | 2011-07-29 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| BR112014005268A2 (pt) | 2011-09-09 | 2017-03-28 | Univ New York | compostos de amido como moduladores de ror t e usos dos mesmos |
| WO2013079223A1 (en) | 2011-12-02 | 2013-06-06 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| US20130190356A1 (en) | 2011-12-22 | 2013-07-25 | Genentech, Inc. | Benzyl sulfonamide derivatives as rorc modulators |
| CN107007597A (zh) | 2012-05-31 | 2017-08-04 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途 |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| WO2014093191A1 (en) | 2012-12-12 | 2014-06-19 | Merck Sharp & Dohme Corp. | AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| JP6368776B2 (ja) | 2013-06-04 | 2018-08-01 | アクチュラム・ライフ・サイエンス・アクチエボラーグ | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 |
| JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| JP6397488B2 (ja) | 2013-09-20 | 2018-09-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| KR20160070823A (ko) * | 2013-10-15 | 2016-06-20 | 얀센 파마슈티카 엔.브이. | RORγt의 헤테로아릴 결합 퀴놀리닐 조절제 |
| ES2742843T3 (es) | 2013-10-15 | 2020-02-17 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo de ROR(gamma)t |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| UA117941C2 (uk) | 2013-12-05 | 2018-10-25 | Лід Фарма Холдінг Б.В. | МОДУЛЯТОРИ ROR-ГAMMA (RORγ) |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
| CN106061947B (zh) | 2014-01-06 | 2019-12-03 | 百时美施贵宝公司 | 环己基砜RORγ调节剂 |
| WO2015103510A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Heterocyclic sulfone as ror-gamma modulators |
| WO2015103508A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | CARBOCYCLIC SULFONE RORγ MODULATORS |
| WO2015103509A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators |
| TWI659019B (zh) | 2014-02-28 | 2019-05-11 | 日商帝人製藥股份有限公司 | 吡唑醯胺衍生物 |
| CN104926733B (zh) * | 2014-03-18 | 2019-05-10 | 北京韩美药品有限公司 | 作为RORγ调节剂的化合物 |
| WO2015145371A1 (en) | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
| CN103833672A (zh) | 2014-03-28 | 2014-06-04 | 中国药科大学 | 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法 |
| WO2016039408A1 (ja) | 2014-09-11 | 2016-03-17 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2016069978A1 (en) | 2014-10-30 | 2016-05-06 | Janssen Pharmaceutica Nv | AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORγT |
| EP3212641B1 (en) | 2014-10-30 | 2018-12-05 | Janssen Pharmaceutica NV | Thiazoles as modulators of roryt |
| TWI667230B (zh) * | 2014-10-30 | 2019-08-01 | 比利時商健生藥品公司 | 用作ＲＯＲγｔ調節劑之三氟甲基醇 |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| JP2020059651A (ja) | 2016-12-26 | 2020-04-16 | 科研製薬株式会社 | ピラゾール誘導体及びそれを含有する医薬 |
| FR3065000A1 (fr) | 2017-04-06 | 2018-10-12 | Galderma Research & Development | Derives pyrazoles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| CA3103770A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of roryt |
| EP3806958B1 (en) | 2018-06-18 | 2022-09-07 | Janssen Pharmaceutica NV | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
| JP2021528405A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
| ES2925473T3 (es) | 2018-06-18 | 2022-10-18 | Janssen Pharmaceutica Nv | Pirazoles de piridinilo como moduladores de RORyt |
-
2017
- 2017-04-25 TW TW106113710A patent/TW201803869A/zh unknown
- 2017-04-26 CR CR20180505A patent/CR20180505A/es unknown
- 2017-04-26 CN CN201780040332.4A patent/CN109415358B/zh not_active Expired - Fee Related
- 2017-04-26 WO PCT/US2017/029531 patent/WO2017189661A1/en not_active Ceased
- 2017-04-26 EP EP17733165.9A patent/EP3448856B1/en active Active
- 2017-04-26 PE PE2018002176A patent/PE20190150A1/es unknown
- 2017-04-26 US US15/497,565 patent/US10975068B2/en not_active Expired - Fee Related
- 2017-04-26 EA EA201892438A patent/EA036318B1/ru not_active IP Right Cessation
- 2017-04-26 CA CA3022318A patent/CA3022318A1/en active Pending
- 2017-04-26 MA MA044772A patent/MA44772A/fr unknown
- 2017-04-26 MX MX2018013143A patent/MX2018013143A/es unknown
- 2017-04-26 JP JP2018556297A patent/JP6893218B2/ja not_active Expired - Fee Related
- 2017-04-26 ES ES17733165T patent/ES2906258T3/es active Active
- 2017-04-26 AU AU2017255525A patent/AU2017255525A1/en not_active Abandoned
- 2017-04-26 SG SG11201809162XA patent/SG11201809162XA/en unknown
- 2017-04-26 KR KR1020187033945A patent/KR20180135962A/ko not_active Ceased
- 2017-04-26 BR BR112018071942A patent/BR112018071942A2/pt not_active Application Discontinuation
- 2017-04-27 AR ARP170101078A patent/AR108344A1/es unknown
- 2017-04-27 UY UY0001037213A patent/UY37213A/es unknown
-
2018
- 2018-10-15 IL IL262381A patent/IL262381A/en unknown
- 2018-10-16 PH PH12018502209A patent/PH12018502209A1/en unknown
- 2018-10-25 CL CL2018003044A patent/CL2018003044A1/es unknown
- 2018-10-26 SV SV2018005772A patent/SV2018005772A/es unknown
- 2018-10-26 NI NI201800109A patent/NI201800109A/es unknown
- 2018-10-29 CO CONC2018/0011633A patent/CO2018011633A2/es unknown
- 2018-11-26 EC ECSENADI201888146A patent/ECSP18088146A/es unknown
-
2021
- 2021-02-23 US US17/182,363 patent/US20210221804A1/en not_active Abandoned
- 2021-02-23 US US17/182,387 patent/US20210188836A1/en not_active Abandoned
- 2021-02-23 US US17/182,375 patent/US20210198251A1/en not_active Abandoned
-
2022
- 2022-12-19 US US18/084,427 patent/US20230123208A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6893218B2 (ja) | ＲＯＲγｔのモジュレータとしての６−アミノピリジン−３−イルチアゾール | |
| JP7664947B2 (ja) | Ｉｌ－１７の調節因子としてのイミダゾリダジン | |
| US20260098036A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| JP7153647B2 (ja) | Ｊａｋファミリーのキナーゼの阻害剤としてのイミダゾピロロピリジン | |
| JP2022533023A (ja) | 統合的ストレス経路の調節剤としての置換シクロアルキル | |
| JP7212763B2 (ja) | ＫＥＡＰ１－Ｎｒｆ２タンパク質－タンパク質相互作用の阻害剤 | |
| JP6998204B2 (ja) | Ｒｏｒγｔのモジュレーターとしてのトリフルオロメチルアルコール | |
| JP2023548169A (ja) | 統合的ストレス経路の調節剤 | |
| JP2021528398A (ja) | ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール | |
| ES2627010T3 (es) | Antagonistas de octahidro-ciclopentapirrolilo de CCR2 | |
| HK40005171B (en) | 6-aminopyridin-3-yl thiazoles as modulators of ror gamma t | |
| HK40005171A (en) | 6-aminopyridin-3-yl thiazoles as modulators of ror gamma t | |
| HK1210783B (en) | Octahydro-cyclopentapyrrolyl antagonists of ccr2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190531 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210326 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210525 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6893218 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |